

SPECIAL REPORT

A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions

Gemma A. Figtree¹; Keith Broadfoot; Barbara Casadei²; Robert Califf³; Filippo Crea⁴; Grant R. Drummond⁵; Jane E. Freedman⁶; Tomasz J. Guzik; David Harrison; Derek J. Hausenloy; Joseph A. Hill⁷; James L. Januzzi; Bronwyn A. Kingwell⁸; Carolyn S.P. Lam; Calum A. MacRae; Frank Misselwitz⁹; Tetsuji Miura¹⁰; Rebecca H. Ritchie¹¹; Maciej Tomaszewski¹²; Joseph C. Wu¹³; Junjie Xiao; Faiez Zannad¹⁴

ABSTRACT: While we continue to wrestle with the immense challenge of implementing equitable access to established evidence-based treatments, substantial gaps remain in our pharmacotherapy armament for common forms of cardiovascular disease including coronary and peripheral arterial disease, heart failure, hypertension, and arrhythmia. We need to continue to invest in the development of new approaches for the discovery, rigorous assessment, and implementation of new therapies. Currently, the time and cost to progress from lead compound/product identification to the clinic, and the success rate in getting there reduces the incentive for industry to invest, despite the enormous burden of disease and potential size of market. There are tremendous opportunities with improved phenotyping of patients currently batched together in syndromic “buckets.” Use of advanced imaging and molecular markers may allow stratification of patients in a manner more aligned to biological mechanisms that can, in turn, be targeted by specific approaches developed using high-throughput molecular technologies. Unbiased “omic” approaches enhance the possibility of discovering completely new mechanisms in such groups. Furthermore, advances in drug discovery platforms, and models to study efficacy and toxicity more relevant to the human disease, are valuable. Re-imagining the relationships among discovery, translation, evaluation, and implementation will help reverse the trend away from investment in the cardiovascular space, establishing innovative platforms and approaches across the full spectrum of therapeutic development.

Key Words: atherosclerosis ■ cardiovascular system ■ drug discovery ■ drug therapy ■ heart failure ■ organoids ■ precision medicine ■ therapeutics

Cardiovascular disease is the leading cause of death globally, with a resurgence in high-income countries, and ongoing rapid rise in low- and middle-income countries.^{1–3} Initiatives to improve equitable access to and implementation of established effective therapies (eg, statins) continue to be an international challenge. However, substantial gaps remain in our pharmacotherapy armament for common forms of cardiovascular disease, including coronary and peripheral arterial disease, heart failure, hypertension, and arrhythmia. Collaborative efforts to tackle access and affordability issues need to be combined with initiatives to accelerate new therapeutic discovery and development. Integration of health economic

analyses at all stages of the development and trial pipeline, which take into consideration the perspective of those who pay for healthcare relevant to the different jurisdictions, is a critical factor for successful and equitable implementation. Currently, the time and cost to progress from lead compound/product identification to the clinic, and the success rate in getting there, reduces the incentive for industry to invest, despite the substantial burden of disease and potential market size. Re-imagining the relationship between discovery, translation, and implementation is required to rapidly reverse these trends. This can be achieved by establishing innovative platforms and approaches across the full spectrum of therapeutic development, and re-

Correspondence to: Gemma A. Figtree. Email gemma.figtree@sydney.edu.au

Graphic Abstract: An online [graphic abstract](#) is available for this article.

For Sources of Funding and Disclosures, see page 168.

This article has been co-published with permission in the *European Heart Journal* and *Circulation*. All rights reserved. © the Author(s) 2021.

Circulation is available at www.ahajournals.org/journal/circ

establishing a thriving and impactful sector capable of discovering and translating new solutions.

WHERE ARE WE NOW?

While there have previously been limited specific data on development of cardiovascular drugs, and factors associated with success of new therapies in clinical trials, Hwang et al⁴ have provided an excellent quantitative analysis of the field. Prior to this, reports had anecdotally suggested that the number of new cardiovascular drugs approved by the US Food and Drug Administration (FDA) had recently declined,^{5,6} and that there was a contraction in the pool of drugs under development targeting cardiovascular disease.⁷ Using the large commercial database of drug development activity (Citeline Pharmaprojects, Informa plc), Hwang et al were able to quantify the rate and ultimate success of translation along the pipeline of over 50 000 products for all diseases, and to compare the rates among disease states, as well as examine factors associated with success. These data confirmed that the number of new cardiovascular drugs entering clinical trials at all stages of development declined between 1990 and 2012 (compared with cancer which increased). Many cardiovascular drugs in development were targeted against modifiable risk factors and previously proven mechanisms addressing these risks including antihypertensive agents, lipid-modifying agents, and anticoagulants. However, 50% of cardiovascular drugs entering Phase III trials between 1990 and 2012 were categorized as targeting novel biological pathways, with this rate of novelty increasing over the time period. Most clinical trials for cardiovascular drugs were sponsored by large pharmaceutical companies. Smaller companies were observed to be active, but more focused on rarer forms of cardiovascular disease. In all three phases of study, the proportion of cardiovascular trials sponsored by large pharmaceutical companies compared with small- or medium-sized companies was significantly greater than that for non-cardiovascular trials.⁴

At the center of the disparity between cardiology and oncology is the lack of routine clinical access to tissue in cardiac and vascular diseases, which has led to disease classifications and thus clinical trials focused to a large extent on phenotypes that aggregate relevant visible properties. These phenotypes, while often linked by final common pathways, typically reflect heterogeneous underlying etiologies and thus responses to intervention. Therefore, efforts in cardiology (and other specialties) to reclassify or stratify diseases based on discrete pathogenetic mechanisms have been proposed as one rational approach to resolving the trend away from cardiovascular therapeutic development. Identification of etiologically homogeneous subgroups of patients (endotypes) within a heterogeneous population is a goal of stratified

medicine but remains a challenge. For instance, Type 1 myocardial infarction is a phenotype that is caused by different endotypes needing different forms of therapy,⁸ which may not be readily defined by current techniques. Similarly, angina is a phenotype that is caused by different endotypes,⁹ but we have tended to focus only on the endotypes for which we have efficient interventions (ie, macrovascular obstruction).

This and some of the additional challenges and potential solutions are outlined below and summarized in the Table.

RESIDUAL RISK AND “MISSING” BIOLOGY

While it remains critical to target the major modifiable risk factors that we do know of, unraveling novel mechanisms particularly relevant to differences in individual susceptibility and resilience to common disease should not be neglected. Many medications in cardiovascular disease have been identified through serendipity, for example, none of the major classes of drug treatment for heart failure (renin-angiotensin-aldosterone inhibitors, beta-blockers, SGLT2 inhibitors), were initially developed for the syndrome. Not surprisingly, drugs discovered in this manner do not appear to address all of the pathophysiologic components of the diseases which they are now used to treat. For example, up to 27% of ST-elevation myocardial infarction patients do not exhibit traditional modifiable risk factors,^{12,13} and a substantial proportion of patients with coronary artery disease (CAD) progress rapidly to recurrent acute events despite optimal medical management.¹⁴ The recent successful trials addressing the residual risk driven by inflammation (CANTOS¹⁵ and LoDoCo2¹⁶) are examples demonstrating that cardiovascular events can be further reduced by therapies acting beyond traditional risk factors. A major limitation of these trials, however, is that they have included the broad population of patients with cardiovascular disease rather than the “endotype” susceptible to an anti-inflammatory treatment.¹⁷

There is significant potential to address these gaps through systematic reappraisal of the mechanisms of the constituent disorders, and the application of proven methods of drug discovery to the resultant novel mechanistically robust targets. For quite some time cardiovascular discovery efforts have been dominated by a multitude of signaling pathways, emerging from large-scale profiling technologies, which while they often provide molecular phenotyping,¹⁸ often lie downstream of the actual causal factors and in many instances may represent compensatory pathways, at least partially explaining the mixed results that have been observed. For example, of the >150 genetic loci reproducibly associated with CAD to date, very few are thought to act via traditional risk factors.¹⁹ Pipelines focused on discoveries from genome-wide

Table. Challenges and Potential Solutions for Accelerating Drug Discovery and Translation in the Cardiovascular Space

Challenges	Potential solutions
Historic tendency to target biological mechanisms which have empirically been shown to influence overall outcomes, rather than definitive disease mechanisms (necessary and sufficient) identified in a discrete subset. Thus ~50% of agents entering Phase III clinical trials still target blood pressure, lipids, and coagulation, ⁴ with limited novel therapeutic targets beyond these.	Identification of definitively causal (not association) novel targets and pathways from robust studies of increasingly homogeneous phenotypic subsets through improved use of molecular and advanced imaging and clinical markers. Increasing proportion of cardiovascular drugs entering Phase III trials targeting novel causal biologic pathways. ^{4,10}
Limitations in methods that target known signaling pathways involved in disease processes.	Advances in drug design platforms will accelerate translation of complex mechanistic knowledge to new therapies.
Poor translation of safety and efficacy parameters from preclinical models (especially rodents) to humans.	Development of mechanistically faithful human ex vivo cardiac and vascular organoids, and the creation of similarly robust animal models that do not just mimic the human condition, but rather reflect the definitive mechanisms, and the burden of comorbidities and age.
Lack of rigor in some preclinical research (eg, single center, not blinding, or randomizing, no protocol publication, over emphasis of findings) contributes to well-recognized limited reproducibility.	Leadership and cultural shift to increased rigor, broader sharing of successes or failures and empiric evaluation of the translatability of the relevant models. Multicenter research networks for preclinical testing.
Challenges with respect to demonstrating efficacy in long-term follow-up Phase III cardiovascular outcome (MACE) trials which are large and expensive relative to other disciplines such as oncology (where putative surrogates such as reduced tumour size are acceptable).	Sub-phenotyping of cardiovascular patients (eg, advanced imaging, or “omics”) to permit more precise targeting of therapies based on biological mechanisms, increased therapeutic effect sizes and consequent reduction in clinical trial sample sizes. Staged regulatory models which include: Use of validated mechanistic endpoints for initial registration Subsequent Phase III clinical trials to determine efficacy with respect to MACE and safety Real-world clinical trial capacity to continue to examine both efficacy and safety Innovative trial designs including healthcare system/registry enrolled Phase III trials (eg, SWEDEHEART, Orion 4, Astra-Zeneca, Farxiga fast-tracked by FDA for heart failure following acute MI ¹¹).
Justifiable reliance on RCT as the dominant method of proving efficacy and safety of a new agent.	Increased uptake of innovative, more efficient study designs including A/B testing or formal randomization within the electronic medical record.
Paucity of repositioning strategies.	Systematic assessment of existing non-cardiovascular drugs, testing their potential for repurposing for cardiovascular conditions.
Slow innovation cycle in cardiovascular medicine.	Strategies and incentives to promote the efficient implementation of interventions that are already known to work—with a focus on equity.
Apathy in the community, government, and private insurance companies—that cardiovascular disease is all “solved” and that we have effective treatments.	Raise awareness of the significant health and economic burden of cardiovascular diseases within the community. Particular focus on the many groups that are susceptible to disease progression and clinical events despite current evidence-based management.
Identifying meaningful outcomes for patients	Rigorous application of patient-reported outcome and patient-reported experience measures.

MACE, major adverse cardiovascular events; RCT, randomized controlled trials.

association studies have been employed by a number of the leading Pharma companies for over a decade, but new causal pathways and successful interventions based on such targets have been slow to emerge.

TECHNOLOGY TO TARGET NOVEL BIOLOGY

The technologies to efficiently develop new therapeutics once definitive targets have been identified are maturing and approaches including in silico screening, fragment-based drug discovery, and tagged libraries have changed the pace of modern drug discovery.²⁰ An expanded tool kit of molecular targeting through cell, gene, RNA, peptide, and protein (including antibody) therapies and nanoparticle technology provide further diversity of approaches and enhance the likelihood of success against

any target.^{21,22} RNA and gene therapies offer remarkable specificity and safety profiles with successful “platform” approaches to therapeutic development. For example, the siRNA Inclisiran (Novartis) represents a powerful approach to sustained inhibition of PCSK9 to reduce LDL-cholesterol. The top 10 (2019) highest growing pharmaceutical companies that are using artificial intelligence (AI) or machine learning for drug discovery have been recently reviewed.²³

PATIENTS WITH RECURRENT EVENTS DESPITE BEST EVIDENCE-BASED CARE: AN OPPORTUNITY FOR NOVEL AGENTS

The current unmet need in cardiovascular disease is exemplified by the substantial number of individuals who develop disease or progress despite best practice treat-




Figure 1. Schematic representation and summary of five patient groups with unmet need for new therapeutic approaches. CAD indicates coronary artery disease; EF, ejection fraction; HF, heart failure; LV, left ventricular; SMuRFLESS, standard modifiable cardiovascular risk factors; and STEMI, ST-segment–elevation myocardial infarction.

ment. Examples include resistant hypertension (estimated to be ~10% of the hypertensive population) and those with advanced atherosclerosis and MI, but no in Standard Modifiable cardiovascular Risk Factors (“SMuRF”-less; between 15% and 30% of ST-elevation MI^{12,13} above threshold). A key goal is to define those individuals at risk of rapid cardiovascular disease progression, in a manner similar to metastatic malignancy, where new agents can be rapidly tested in small sample sizes due to higher event rate. This approach permits elucidation of novel biological mechanisms not currently addressed by existing agents (Figure 1). For instance, recent data suggest that failure of plaque healing might help explain recurrent acute coronary events and might become a new therapeutic target.²⁴ A consensus definition of those who rapidly progress to have recurrent events for atherosclerosis, heart failure, or other disorders, despite best

evidence-based therapies may also provide enhanced opportunities to define underlying mechanisms, and to augment the power for targeted therapeutic studies. Similarly, angina or myocardial infarction without obstructive coronary disease, a cause of substantial morbidity with unmet need, might usefully be defined using population-level diagnostics for coronary microvascular dysfunction which could then drive rigorous mechanistic studies and improved targeted therapies.²⁵

PRECISION MEDICINE AND DRUG DEVELOPMENT

Common disease states impacting cardiovascular health and driving morbidity and mortality, such as atherosclerosis and heart failure, are multi-factorial and have been shown to consist of many different sub-groups, each

presumed to be driven by a distinct, predominant mechanism (as yet unknown). An extreme example is the syndrome of heart failure which is divided into subgroups based on left ventricular ejection fraction being either reduced (HFrEF) or preserved (HFpEF). Interestingly, HFrEF patients with widely diverse etiologies—from prior myocardial infarction, to chronic ischemia, to inflammatory and infiltrative conditions, and through to dilated cardiomyopathy of uncertain etiology—all appear to gain some benefit from the same neurohormonal agents. In contrast, clinical trials of patients with HFpEF have been consistently neutral,²⁶ up until the recent observation of potential benefit with the SGLT2 inhibitor class of drugs^{27,28} currently under rigorous prospective evaluation in large-scale clinical trials.²⁹ Our relative failure in this common clinical syndrome may partly relate to the even more broad spectrum of phenotype cluster, which not only includes individuals with bona fide physiologic abnormalities of relaxation, eg, cardiac amyloidosis and restrictive cardiomyopathy, but also an amalgam of conditions where non-cardiac comorbidities and abnormalities contribute, and the only cardiac abnormalities may be changes in load-dependent indices of diastolic physiology which may represent a range of disorders from deconditioning to poorly treated hypertension.^{30,31} A similarly complex spectrum of “phenotypes” and etiologies, regarding individual patterns of response to classic risk factors, likely exists for atherosclerosis.³² Better stratification by underlying mechanistic markers will be required to make the next advances in the prevention and treatment of these conditions.

Current clinical trials, and subsequently guidelines, of necessity tend to “bundle” patients together based on the aggregated syndromes referred to above. While the evidence-based treatment likely acts on common parts of the pathway, and some pharmaceutical companies would prefer to design validation phases to provide as “wide” a market as possible, this may hinder larger leaps relevant to smaller more etiologically pure subgroups. Advances in disease stratification tools (including molecular and advanced imaging technologies) to identify more specific patient populations will help to unravel new mechanisms in these subgroups, and lead to better targeting of new therapies. Ultimately, these same mechanisms will also be useful to identify potential novel endpoints that will also accelerate subsequent focused clinical trials. In other words, time has perhaps come to improve the balance and give more emphasis to “splitting” rather than “lumping.”

Artificial intelligence and machine learning approaches are being used to better cluster patient populations and derive more tightly circumscribed patient cohorts. This patient segmentation may derive patient endotypes, but this will likely require a systematic improvement in the information content of phenotypic assessment. Both unsupervised and supervised machine learning approaches are currently being used to better character-

ize patients with heart failure and those who have had a stroke. Among these efforts are electronic health record-based explorations of several million patients with longitudinal follow-up data (up to 7 years) in a collaboration with the Broad Institute at Harvard and MIT, Boston, MA, USA, as well as with Sensyne Health in Oxford, UK. The American Heart Association has also invested substantially in the Precision Medicine Initiative. The resulting datasets offer the opportunity to train models against discrete outcomes and then validate these in prospectively collected data from randomized controlled trials (RCT). Such approaches aim to improve inclusion or exclusion of patients in future clinical trials targeting more distinctly stratified patient cohorts, but ultimately definitive new biology will be required to define new targets.

A more immediate application of genomics to drug development is the relatively simpler application of pharmacogenomics, where variants at a specific locus are known to alter the metabolism or response to therapeutic agents. There has been mixed support for such an approach from the pharmaceutical industry, yet targeting drugs to specific mechanisms in individuals might streamline development pathways with smaller trials and ultimately lead to higher efficacy and safety as well as better outcomes for patients. In the case of clopidogrel, warfarin, and statins, drugs already well-established, the literature has become sufficiently strong that guidelines are now available to help implement the use of genetic information to guide treatment with these therapies.³³ The cost-effectiveness of implementing these insights has been difficult to prove, with relatively weak benefit on outcomes observed in clinical studies, and so the prospective development and validation of new therapies for patients with specific genotypes have not been broadly undertaken.

NEGLECTED FORMS OF CARDIOVASCULAR DISEASE CONTRIBUTING TO THE BURDEN OF DISEASE IN LOW- AND MIDDLE-INCOME COUNTRIES

It is estimated by the World Health Organization that 75% of the burden of cardiovascular disease across the globe is found in low- and middle-income countries.³⁴ While a major component of this is shared with higher-income countries—in regard to ischemic heart disease, cerebrovascular disease and hypertension—neglected tropical diseases, and other infections associated with poverty account for a significant proportion of these cardiovascular categories.^{35,36} It is well recognized that tackling these conditions—such as rheumatic heart disease, endomyocardial fibrosis, and Chagas Disease—require public health and policy solutions and equitable implementation of existing evidence. However, there are many stages of the disease where new drug therapies are ur-

gently needed, working with governments and clinicians to consider pragmatic issues around delivery and affordability at all stages of development.

ADVANCES IN IN VITRO HUMAN MODELS OF CARDIOVASCULAR DISEASE

Pharmacological studies have long been a centerpiece of non-clinical drug evaluation prior to in vivo studies. Well-defined cellular models enabling investigators to screen chemical compound libraries and drug candidates have then been selected for secondary validation screens. Perhaps more than other organs, there is a need for in vitro models that better represent the human heart to understand cellular mechanisms and to test new therapies.³⁷ Several teams around the world have made recent progress on this front by moving from 2D monolayer cultures to 3D spheroids, organoids, or microphysiological systems. This includes both primary cardiac myocytes, or induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), along with co-culturing approaches which incorporate endothelial cells,³⁸ and cardiac fibroblasts.³⁹ Such approaches not only enhance the modeling of human heart behavior but also prolong the survival of human cardiac myocytes in culture.⁴⁰ For example, Mei and colleagues have established a model of myocardial infarction in human cardiac organoids that utilizes both hypoxia and noradrenaline and recapitulates pathological metabolic, fibrosis, and calcium handling changes at the transcriptomic, structural, and functional level.³¹ Hudson and team have developed a bioengineered human cardiac organoid platform that provides functional contractile tissue with biological properties similar to native heart tissue. Moreover, the team have applied this model to screen small molecules with pro-regenerative potential, demonstrating that while some small molecules were pro-regenerative, they had the unintended side effect of decreasing contractility.³² Similarly, Takeda et al⁴¹ have demonstrated the potential of 3D cardiac tissue derived from human iPSC-CMs to screen for drug-induced cardiotoxicity. Such approaches have the potential to support early drug screening and tackle the biggest gaps in our drug armament; but it will be vital to improve the uniformity of the organoids at the scale necessary for empiric screening, and proof of translatability remains a challenge for all preclinical models in the cardiovascular space. If successful, this will be a major step forward in overcoming the limitations related to our minimal access to the tissues and cells at the center of the disease.

IN VIVO TRANSLATIONAL MODELS

Robust demonstration of both proof-of-mechanism and efficacy in animal disease models is a critical step in drug

development that must be achieved prior to progression to human trials. The cardiovascular field is littered with numerous examples of therapies that show great promise in preclinical studies yet fail during the clinical trial phase. A major challenge for cardiovascular drug development, that is shared by other disease groups, is the failure of many small animal (usually rodent) models to fully reproduce human diseases. For example, rodents are particularly resistant to the development of atherosclerosis, and even more so to the development of unstable plaques. Furthermore, interventions found to be successful in preclinical animal models have been poor at predicting successful intervention in human studies. While the reasons for this are not fully understood, they are at least partly related to fundamental species differences in hemodynamics, lifespan, lipid metabolism (eg, absence of the cholesteryl ester transfer gene in rodents)⁴² and immune function.⁴³ Similar difficulties in adequately replicating disease parameters in animal models for other human cardiovascular pathologies, including cardiac arrhythmias (where species differences in cardiac electro-mechanical coupling confound model development⁴⁴) HFpEF, and resistant hypertension, have plagued translation of discovery research into the clinic. Typically, cardiovascular disease models are agnostic to the actual disease mechanisms in humans, not least because there is insufficient information available regarding the biology in humans as a result of the logistical challenges of obtaining human cardiac and vascular disease tissues.

Practices that are routine in clinical research, such as a priori sample size and power calculations, randomization, blinding, and the use of appropriate statistical analyses, were frequently overlooked in preclinical studies, particularly in academic research. Other factors, such as clearly defined inclusion and exclusion criteria, littermate controls, full disclosure of all collected data, and confirmation of findings across multiple labs, have historically often been lacking in academia.^{45–47} Many cardiovascular models are “accelerated,” for example employing animal models in which the disease phenotype of, eg, atherosclerosis or heart failure develops over weeks rather than months to years, and/or utilizing young animals despite the fact that in humans most cardiovascular diseases present during middle age or beyond. Similarly, many therapies are tested in remarkably few genotypes before clinical use, so that relatively rare adverse events may not be detected. Likewise, cardiovascular morbidities seldom present in isolation from other comorbidities, yet few studies focus on animal models that combine multiple diseases (eg, superimposing comorbidities such as obesity or hypertension onto the model of interest). Finally, the overwhelming majority of animal studies only use males and thus likely fail to model key disease mechanisms present in females, failing to represent half of the patients for whom these therapies are intended in the real world.

How can the field be improved? First and foremost is the need for rigorous mechanistically faithful models for the indication of interest. Attention to those models which have proven translatability for safety and efficacy in previous drug development programs would also be useful.⁴⁶ Where there are no mechanistic models, efforts are likely best focused on human studies to define causal mechanisms. In many instances, there is also a need for large animal models, as a bridge between rodent studies and human trials, but here too the need for mechanistic representation cannot be overstated. Finally, closer attention must be paid to best practice in experimental design. In this regard, guidelines such as ARRIVE (Animal Research: Reporting of In Vivo Experiments)⁴⁸ and STAIR (Stroke Therapy Academic Industry Roundtable),⁴⁹ modeled after the CONSORT (Consolidated Standards for Reporting Trials) statement for clinical research provide an excellent roadmap. As such, a template flow diagram for reporting animal use and analysis in preclinical studies has been developed,⁴⁵ the Consolidated Standards of Animal Experiment Reporting (CONSAERT) template.

Choosing the right models and the right endpoints, as well as empirically defining the extent to which the modeled biology and response to intervention translate into humans, should be a quantitative metric for filing with regulatory agencies to move towards clinical studies. This requirement would also enable such data to be made public in a protected manner, thus enabling progressive optimization of the drug development process.

TRANSITION TO A STAGED APPROACH FOR REGULATORY EVALUATION OF THERAPIES BASED ON CLINICALLY AND MECHANISTICALLY RELEVANT MEASURES OF BENEFIT AND SAFETY

The high bar that the cardiovascular field has set, with primary endpoints focused on mortality except when validated surrogates are available are in sharp contrast with oncology in which unvalidated surrogate endpoints are frequently accepted, creates an unfortunate backlash of disincentivizing investment due to high costs, and high risk. While being careful not to lower the ultimate bar, collaborative effort to identify reproducible markers of benefit and safety that could be tested in a staged approach, may be required to ensure efficiency of the cycle, and ongoing investment in the development of cardiovascular drugs. A focus on what is important to the patient, as well as on the biology underlying a more precise disease taxonomy, will be important.

In 2015, the FDA approved alirocumab and evolocumab, monoclonal antibodies to PCSK9, for high-risk patients, prior to the large cardiovascular outcome trials being completed⁴ due to their benefit on lipid profiles in those who were already maximally treated. This is not

dissimilar to the pathway that the diabetic field has taken as required by FDA regarding glucose-lowering treatments, and the oncology field with cancer “shrinkage.” In each instance, there is a substantial tension between such limited approval and the need for demonstration of definitive benefit and avoidance of harm for patients in terms of morbidity and mortality. Innovation in patient-reported or functional endpoints can be accelerated with the arrival of wearables and other new technologies. There is some potential for advances in non-invasive imaging of the myocardium (eg, post-contrast myocardial T1 mapping for cardiac fibrosis⁵⁰) and atherosclerosis (eg, serial CT coronary angiography and plaque characterization⁵¹) to enhance the power of early phase trials for relevant drugs, but it will be vital to improve the rigorous mapping of such metrics onto meaningful patient outcomes. The “hard” endpoints required for new agents for management of myocardial infarction, heart failure, or most primary prevention drugs is a consequence of prior adverse outcomes when such putative surrogates were employed. Improving our approaches to defining and testing new endpoints will be a central requirement to advance cardiovascular drug discovery. The advent of real-world tools and large-scale analytics may aid this process, but here again increased information content will likely be necessary to escape the constraints of existing disease nosology and the resultant decades of downstream selection bias. Regulatory agencies have strong track records responding to patient-centered outcomes, and the cardiology community is actively increasing the use of such metrics and novel trial designs to transform the approaches to translational science in the field. A collaborative effort working with regulatory agencies to develop a staged approach may allow for acceleration of efficacious therapies, reducing time and cost, but not rigor and safety.

A key consideration at all phases of research and development (R&D) of new drug solutions is equity. The exclusion of minority ethnic groups and women, as well as poor representation of low-income countries, has been a detriment to the field and ignores the burden of disease, with ~75-80% of cardiovascular disease deaths occurring in low- and middle-income countries.

There is increasing appreciation of the importance of early engagement with patients and the community in regard to endpoints that are most relevant and important to them. In this regard, it is critical that the cardiovascular sector is proactive in patient and community engagement in the design of studies, and in developing innovative measurement of patient-reported outcomes and experiences. Such patient-reported outcomes can be captured electronically or in person through formats ranging from questionnaires to wearable devices and are used to provide a quantifiable record of the patient's lived experience of a disease. The inclusion of such measures as trial endpoints allows for a more comprehen-

sive assessment of the burden of disease and the impact of an intervention.⁵² However, for such endpoints to be accepted as useful indicators by regulatory bodies and professional guideline developers, we need to ensure that they are validated as prognostically significant and reflecting the underlying pathology, as well as being reliable and reproducible.

INNOVATIVE CLINICAL TRIAL DESIGN

It is likely that disease heterogeneity diminishes the average therapeutic effect. Because of these modest effect sizes, the large-scale, long-term follow-up Phase III clinical trials needed to demonstrate the effect of interventions on the essential outcomes of cardiovascular disease (“hard” cardiovascular endpoints of mortality or combined major adverse cardiovascular events) are expensive and require time for follow-up. Consensus-building between pharmaceutical manufacturers and regulatory bodies, and the inclusion of multiple other stakeholders to ensure meaningful problems are addressed directly, is a key factor for consideration.⁵³ Diversity of the trial population, specifically with appropriate balance of women and different ethnic groups, rural-urban, wealth, and education differences, could also be significantly improved.⁵³ At the same time, improved stratification based on precise phenotypes will improve power and success. The estimated cost of a Phase III clinical trial for primary prevention in cardiovascular disease is between \$USD250 and 450 million; ~20 times higher than the median estimated cost of Phase III clinical trials overall. Thus, it is possible that improving the efficiency of cardiovascular trials would be an important step to reinvigorate interest, and to accelerate new drug development and translation at all phases of the pipeline.

The advent of electronic health records and potential for routinely collected medical data to populate virtual registries for heart attacks, heart failure, and arrhythmia as examples, are one of a number of opportunities to enhance trial design efficiency and lower costs. Utilization of routinely collected electronic health data will allow self-population of electronic case report form entries to enhance efficiencies of registries and randomized clinical trials. It may also enable the use of additional synthetic or semi-synthetic control arms by matching verum cases with placebo cases from existing patients with the same demographics and baseline characteristics and with an appropriately long enough longitudinal follow-up. Furthermore, the efficient use of electronic medical record data may enhance the integration of the health system with the R&D sector, increasing the proportion of patients with specific conditions participating in trials.

The impact of innovation in clinical studies of novel therapies is evident in Astra Zeneca’s testing of Farxiga

which has been granted Fast Track Designation in the USA for heart failure following acute myocardial infarction leveraging a registry-based trial design.¹¹ Inclisiran (Novartis) is a further example where healthcare system data from the UK’s National Health System is being used to dramatically reduce trial costs by rapidly identifying patient populations through administrative data. This powerful collaboration among academic institutions, government and industry will accelerate development as well as potential market access through the National Institute for Health and Care Excellence’s (NICE) approval program and a population-level commercial arrangement to make it widely accessible to patients.⁵⁴ International networks of clinical trials embedded into efficient health systems with such infrastructure would be a major asset.

Important efficiency gains may be derived from conducting trials directly with the patient-clinician dyad rather than through dedicated trial sites or via specific investigators. This can be further enhanced by utilizing electronic data collection from wearables, and other data collection approaches such as point of care lab tests. Data quality is already dependent on remote monitoring and statistical fraud detection (trained AI algorithms) rather than solely by on-site monitoring visits with source data verification.

WORKING WITH KEY STAKEHOLDERS TOWARDS GLOBAL SOLUTIONS

Despite advances in the processes and organization of clinical guidelines and evidence-based medicine, which would be envisaged to promote the uptake and application of new therapies once proven in large-scale Phase III randomized clinical trials, Pharma face a variety of diverse barriers unique to each nation in regard to federal regulatory authorities and financial reimbursement policies. This requires a dedicated “army” of strategic company staff members who are often engaged in expensive lobbying with little logical relationship between the chance and rate of success and the clinical unmet need or demonstrated health and economic benefit. While country-specific approaches will be required, moving beyond geographic borders will be essential. As healthcare globalizes, patients are increasingly demanding increased access to the latest innovations and are willing to go beyond their current clinical relationships to gain such access. In developing solutions likely to be effective in improving the success of cardiovascular drug development, we should learn from the oncology field where clinical trials are more tightly integrated into clinical care in a much more rapid cycle innovation framework. This will require transformation of the culture of cardiovascular care which often is balkanized on the basis of acuity and revenue for healthcare systems. Such culture change might best be focused on the creation of robust approaches to the implementation




Figure 2. Call to action: collaborative next steps to accelerate discovery, translation, and impact in cardiovascular medicine. iPS indicates induced pluripotent stem; and SMuRFLESS, standard modifiable cardiovascular risk factors.

of existing proven therapies, which typically are deployed in a highly variable manner even a decade after reaching consensus endorsement by professional society clinical practice guidelines. Resolving these inequities alone would substantially reduce the cost of drug development, long before the advent of novel targets which would be pursued aggressively in tandem.

Community and government perceptions are often inaccurate, with many believing that much of cardiovascular disease is self-inflicted through poor lifestyle choices, or an inevitable part of aging. This is compounded by the perception that the current armamentarium of drugs for atherosclerosis and heart failure already provide the entire solution. The remaining large gaps in our understanding and targeting of residual risk and missing mechanisms are ever important. A coordinated strategy engaging patients, clinicians, researchers, regulators, and industry needs to be established to focus on the redesign of the cardiovascular drug discovery and development pipeline. Creating a community that provides a common voice to engage all stakeholders including governments, will be a critical first step and such an effort might rationally be convened by collaboration across the relevant professional and patient societies.

NEXT STEPS AND CONCLUDING REMARKS

The COVID-19 Pandemic has provided the community with a poignant example of an acute health problem in urgent need of solutions. Understanding disease

spread and individual susceptibility, as well as discovering new treatments and a vaccine are priorities immediately evident to all. The response of researchers from around the globe, working with healthcare, government leaders and industry, as well as the broader community, demonstrates the committed, diverse and innovative talent that can be mobilized to address our world's major health challenges. The extent of collaboration with industry, including between companies, is also unprecedented.⁵⁵ Yet the lack of any pre-existent structures within the biomedical ecosystem for global coordination against a pandemic some 100 years after the last example speaks to the core deficits at play when there is not an immediate temporal imperative to manage a disease. It is important to remember that in the 12 months of COVID-19 to date, ~18 million individuals around the globe will have died of cardiovascular disease, with the majority from low- and middle-income countries. The time is right to continue the momentum and international collaboration achieved to address COVID-19 and commit to taking similar steps and sustaining these in the fight against cardiovascular disease, our greatest killer (Figure 2). Developing a global approach to transform the drug discovery and translation ecosystem for cardiovascular disease, while maintaining efforts towards equitable access to established effective treatments, is an imperative not an option.

ARTICLE INFORMATION

Received November 26, 2020; revised January 1, 2021; editorial decision January 22, 2021; accepted February 5, 2021.

Affiliations

Kolling Institute, Royal North Shore Hospital, University of Sydney, Australia (G.A.F.). Clinical Committee, National Heart Foundation of Australia (K.B.). Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, UK (B.C.). NIHR Oxford Biomedical Research Centre, UK (B.C.). British Heart Foundation Centre of Research Excellence, Oxford, UK (B.C.). Verily, South San Francisco, CA (R.C.). Catholic University, Rome, Italy (F.C.). Centre for Cardiovascular Biology and Disease Research and Department of Physiology, Anatomy and Microbiology, La Trobe University, Melbourne, Australia (G.R.D.). Cardiovascular Research, University of Massachusetts Medical School, Worcester (J.E.F.). Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK (T.J.G.). Jagiellonian University Collegium Medicum, Krakow, Poland (T.J.G.). Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN (D.H.). Signature Research Program in Cardiovascular & Metabolic Disorders Program, Duke–National University of Singapore NUS Medical School (D.J.H.). National Heart Research Institute Singapore, National Heart Centre (D.J.H.). Yong Loo Lin School of Medicine, National University Singapore (D.J.H.). The Hatter Cardiovascular Institute, University College London, UK (D.J.H.). Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taiwan (D.J.H.). University of Texas Southwestern, Dallas (J.A.H.). Massachusetts General Hospital, Harvard University, Boston (J.L.J.). CSL Ltd, Melbourne, Australia (B.A.K.). National Heart Centre Singapore and Duke–National University of Singapore (C.S.P.L.). Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.A.M.). Bayer AG, Pharmaceuticals Division, Wuppertal, Germany (F.M.). Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University, Japan (T.M.). Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), VIC, Australia (R.H.R.). Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health and Manchester University NHS Foundation Trust, University of Manchester, UK (M.T.). Stanford Cardiovascular Institute, CA (J.C.W.). Cardiac Regeneration and Ageing Laboratory, Institute of Cardiovascular Sciences, School of Life Sciences, Shanghai University, China (J.X.). Université de Lorraine, INSERM CIC 1493, INI CRCT, CHRU, Nancy, France (F.Z.).

Sources of Funding

None.

Disclosures

G.A.F. reports grants from National Health and Medical Research Council (Australia), personal fees from CSL, and grants from Abbott Diagnostic outside the submitted work. In addition, G.A.F. has a patent Biomarkers and Oxidative Stress awarded USA May 2017 (US9638699B2) issued to Northern Sydney Local Health District. Dr B.C. reports in-kind research support from Roche Diagnostics and iRhythm, outside the submitted work. Dr R.C. reports personal fees from Verily, Google Health, and Cytokinetics, during the conduct of the study and outside the submitted work. Dr F.C. reports personal fees from Amgen, AstraZeneca, Servier, and BMS, outside the submitted work. Dr J.E.F., Dr D.H., Dr D.J.H., Dr J.A.H., Dr T.M., Dr M.T., and Dr J.X. have nothing to disclose. Dr G.R.D. and Dr R.H.R. reports grants from National Health and Medical Research Council (Australia), Dr T.G. reports grants and personal fees from Oxford University Press, grants and personal fees from Bayer AG and Merck, outside the submitted work. Dr J.J. reports grants and personal fees from Roche, grants, personal fees, and other contributions from Novartis, grants from Innolife, grants from Applied Therapeutics, personal fees from Abbott, other contributions from Bayer, Siemens, Abbvie, Amgen, and Imbria Pharmaceuticals, during the conduct of the study. Dr B.A.K. reports other contributions from CSL Ltd, outside the submitted work. Dr C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, Vifor Pharma, Novartis, Amgen, Merck, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Novo Nordisk, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd and Corpus; and serves as co-founder and non-executive director of Us2ai. Dr C.A.M. reports grants from NIH, American Heart Association, Verily, AstraZeneca, Quest Diagnostics, Apple, Pfizer, Bayer, BMS, personal fees from Clarify Health Solutions, Foresite Labs, other contributions from Atman Health, outside the submitted work. In addition, Dr C.A.M. has a patent Genetic testing in cardiomyopathies with royalties paid to Partners Health Care, a patent Training cytometry data to refine disease pending, a patent Scalable cellular physiology to refine disease pending, and a patent Annotating small molecule function using phenotypic profiling pending. Dr F.M. reports other contributions from Bayer AG, outside the submitted work. Dr J.C.W. reports grants from National Institutes of Health. Dr F.Z. reports personal fees from Janssen, Novartis, Boston Scientific, Amgen, CVRx, other contributions from cardiorenal, personal fees from AstraZeneca, Vifor Fresenius, Cardior, Cerezo

pharmaceutical, Applied Therapeutics, Merck, other contributions from CVCT, personal fees from BAYER, Cellprothera, Owkin, Boehringer, Myokardia, Corvia, and other contributions from G3 pharmaceuticals, outside the submitted work.

REFERENCES

1. Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos EA, Maggioni AP, Kazakiewicz D, May HT, et al; European Society of Cardiology. European Society of Cardiology: Cardiovascular Disease Statistics 2019. *Eur Heart J*. 2020;41:12–85. doi: 10.1093/eurheartj/ehz859
2. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. *Circulation*. 2020;141:e139–e596. doi: 10.1161/CIR.0000000000000757
3. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 Study. *J Am Coll Cardiol*. 2020;76:2982–3021. doi: 10.1016/j.jacc.2020.11.010
4. Hwang TJ, Lauffenburger JC, Franklin JM, Kesselheim AS. Temporal trends and factors associated with cardiovascular drug development, 1990 to 2012. *JACC Basic Transl Sci*. 2016;1:301–308. doi: 10.1016/j.jacbs.2016.03.012
5. Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, Bristow MR, Packer M, Wasserman SM, Braunstein N, et al. Cardiovascular drug development: is it dead or just hibernating? *J Am Coll Cardiol*. 2015;65:1567–1582. doi: 10.1016/j.jacc.2015.03.016
6. Darrow JJ, Kesselheim AS. Drug development and FDA approval, 1938–2013. *N Engl J Med*. 2014;370:e39. doi: 10.1056/NEJMp1402114
7. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. *Nat Rev Drug Discov*. 2011;10:428–438. doi: 10.1038/nrd3405
8. Crea F, Libby P. Acute coronary syndromes: the way forward from mechanisms to precision treatment. *Circulation*. 2017;136:1155–1166. doi: 10.1161/CIRCULATIONAHA.117029870
9. Kaski JC, Crea F, Gersh BJ, Camici PG. Reappraisal of ischemic heart disease. *Circulation*. 2018;138:1463–1480. doi: 10.1161/CIRCULATIONAHA.118.031373
10. Fiuzat M, Stockbridge N, Califf RM. Resourcing drug development commensurate with its public health importance: the road ahead. *JACC Basic Transl Sci*. 2016;1:309–312. doi: 10.1016/j.jacbs.2016.07.003
11. Farxiga granted Fast Track Designation in the US for heart failure following acute myocardial infarction leveraging an innovative registry-based trial design. 2020.
12. Vernon ST, Coffey S, Bhandi R, Soo Hoo SY, Nelson GI, Ward MR, Hansen PS, Asress KN, Chow CK, Celermajer DS, et al. Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. *Eur J Prev Cardiol*. 2017;24:1824–1830. doi: 10.1177/2047487317720287
13. Vernon ST, Coffey S, D'Souza M, Chow CK, Kilian J, Hyun K, Shaw JA, Adams M, Roberts-Thomson P, Brieger D, et al. ST-segment-elevation myocardial infarction (STEMI) patients without standard modifiable cardiovascular risk factors: how common are they, and what are their outcomes? *J Am Heart Assoc*. 2019;8:e013296. doi: 10.1161/JAHA.119.013296
14. Schiele F, Ecarnot F, Chopard R. Coronary artery disease: risk stratification and patient selection for more aggressive secondary prevention. *Eur J Prev Cardiol*. 2017;24(suppl):88–100. doi: 10.1177/2047487317706586
15. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med*. 2017;377:1119–1131. doi: 10.1056/NEJMoa1707914
16. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, et al; LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. *N Engl J Med*. 2020;383:1838–1847. doi: 10.1056/NEJMoa2021372
17. Crea F, Liuzzo G. Addressing acute coronary syndromes: new challenges and opportunities after the CANTOS trial (Canakinumab Anti-inflammatory Thrombosis Outcomes Study). *Circulation*. 2018;137:1100–1102. doi: 10.1161/CIRCULATIONAHA.117.032178

18. Vernon ST, Hansen T, Kott KA, Yang JY, O'Sullivan JF, Figtree GA. Utilizing state-of-the-art "omics" technology and bioinformatics to identify new biological mechanisms and biomarkers for coronary artery disease. *Microcirculation*. 2019;26:e12488. doi: 10.1111/micc.12488
19. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D, Erdmann J, Goldstein BA, et al; CARDIoGRAM Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. *Nat Genet* 2013;45:25–33.
20. Murray CW, Rees DC. The rise of fragment-based drug discovery. *Nat Chem*. 2009;1:187–192. doi: 10.1038/nchem.217
21. Bubb KJ, Drummond GR, Figtree GA. New opportunities for targeting redox dysregulation in cardiovascular disease. *Cardiovasc Res*. 2020;116:532–544. doi: 10.1093/cvr/cvz183
22. Landmesser U, Poller W, Tsimikas S, Most P, Paneni F, Lüscher TF. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. *Eur Heart J*. 2020;41:3884–3899. doi: 10.1093/eurheartj/ehaa229
23. Pharmacy Infopedia. Top 10 pharmaceutical industries using artificial intelligence. 2020. Accessed March 3, 2021. <https://www.pharmatutor.org/articles/top-ten-pharmaceutical-industries-using-artificial-intelligence>
24. Vergallo R, Crea F. Atherosclerotic plaque healing. *N Engl J Med*. 2020;383:846–857. doi: 10.1056/NEJMra2000317
25. Camici PG, Crea F. Coronary microvascular dysfunction. *N Engl J Med*. 2007;356:830–840. doi: 10.1056/NEJMra061889
26. Yoon S, Eom GH. Heart failure with preserved ejection fraction: present status and future directions. *Exp Mol Med*. 2019;51:1–9. doi: 10.1038/s12276-019-0323-2
27. Figtree GA, Rådholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus. *Circulation*. 2019;139:2591–2593. doi: 10.1161/CIRCULATIONAHA.119.040057
28. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. *Circulation*. 2019;139:2528–2536. doi: 10.1161/CIRCULATIONAHA.119.040130
29. Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, et al; EMPEROR-Preserved Trial Committees and Investigators. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. *Eur J Heart Fail*. 2019;21:1279–1287. doi: 10.1002/ehf.1596
30. Shah SJ. Precision medicine for heart failure with preserved ejection fraction: an overview. *J Cardiovasc Transl Res*. 2017;10:233–244. doi: 10.1007/s12265-017-9756-y
31. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol*. 2017;14:591–602. doi: 10.1038/nrcardio.2017.65
32. Kott KA, Vernon ST, Hansen T, Yu C, Bubb KJ, Coffey S, Sullivan D, Yang J, O'Sullivan J, Chow C, et al. Biobanking for discovery of novel cardiovascular biomarkers using imaging-quantified disease burden: protocol for the longitudinal, prospective, BioHEART-CT cohort study. *BMJ Open*. 2019;9:e028649. doi: 10.1136/bmjopen-2018-028649
33. Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease—implications for personalized medicine. *Pharmacol Rev*. 2013;65:987–1009. doi: 10.1124/pr.112.007252
34. World Health Organization. Projections of mortality and burden of disease, 2004–2030; standard DALYs (3% discounting, age weights) - baseline scenario; 2008; WHO regions. 2011. Accessed November 15, 2020. http://www.who.int/entity/healthinfo/global_burden_disease/DALY7_2008.xls
35. Celermajer DS, Chow CK, Marijon E, Anstey NM, Woo KS. Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection. *J Am Coll Cardiol*. 2012;60:1207–1216. doi: 10.1016/j.jacc.2012.03.074
36. Moolani Y, Bukhman G, Hotez RJ. Neglected tropical diseases as hidden causes of cardiovascular disease. *PLoS Negl Trop Dis*. 2012;6:e1499. doi: 10.1371/journal.pntd.0001499
37. Ebert AD, Liang P, Wu JC. Induced pluripotent stem cells as a disease modeling and drug screening platform. *J Cardiovasc Pharmacol*. 2012;60:408–416. doi: 10.1097/FJC.0b013e318247f642
38. Sayed N, Liu C, Ameen M, Himmati F, Zhang JZ, Khanamiri S, Moonen JR, Wnorowski A, Cheng L, Rhee JW, et al. Clinical trial in a dish using iPSCs shows lovastatin improves endothelial dysfunction and cellular cross-talk in LMNA cardiomyopathy. *Sci Transl Med* 2020;12:eaa9276. doi: 10.1126/scitranslmed.aax9276. AQ15
39. Zhang H, Tian L, Shen M, Tu C, Wu H, Gu M, Paik DT, Wu JC. Generation of quiescent cardiac fibroblasts from human induced pluripotent stem cells for in vitro modeling of cardiac fibrosis. *Circ Res*. 2019;125:552–566. doi: 10.1161/CIRCRESAHA.119.315491
40. Polonchuk L, Chabria M, Badi L, Hoflack JC, Figtree G, Davies MJ, Gentile C. Cardiac spheroids as promising in vitro models to study the human heart microenvironment. *Sci Rep*. 2017;7:7005. doi: 10.1038/s41598-017-06385-8
41. Takeda M, Miyagawa S, Fukushima S, Saito A, Ito E, Harada A, Matsuura R, Iseoka H, Sougawa N, Mochizuki-Oda N, et al. Development of in vitro drug-induced cardiotoxicity assay by using three-dimensional cardiac tissues derived from human induced pluripotent stem cells. *Tissue Eng Part C Methods*. 2018;24:56–67. doi: 10.1089/ten.TEC.2017.0247
42. Ha YC, Barter PJ. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. *Comp Biochem Physiol B*. 1982;71:265–269. doi: 10.1016/0305-0491(82)90252-8
43. Zschaler J, Schlorke D, Arnold J. Differences in innate immune response between man and mouse. *Crit Rev Immunol*. 2014;34:433–454.
44. Milani-Nejad N, Janssen PM. Small and large animal models in cardiac contraction research: advantages and disadvantages. *Pharmacol Ther*. 2014;141:235–249. doi: 10.1016/j.pharmthera.2013.10.007
45. Drucker DJ. Never waste a good crisis: confronting reproducibility in translational research. *Cell Metab*. 2016;24:348–360. doi: 10.1016/j.cmet.2016.08.006
46. Hausenloy DJ, Heusch G. Translating cardioprotection for patient benefit: the EU-CARDIOPROTECTION COST action. *J Am Coll Cardiol*. 2019;73:2001–2003. doi: 10.1016/j.jacc.2019.03.020
47. Lindsey ML, Kassiri Z, Virag JAI, de Castro Brás LE, Scherrer-Crosbie M. Guidelines for measuring cardiac physiology in mice. *Am J Physiol Heart Circ Physiol*. 2018;314:H733–H752. doi: 10.1152/ajpheart.00339.2017
48. Percie Du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. *PLoS Biol*. 2020;18:e3000410. doi: 10.1371/journal.pbio.3000410
49. Savitz SI, Baron JC, Fisher M; STAIR X Consortium. Stroke Treatment Academic Industry Roundtable X: brain cytoprotection therapies in the reperfusion era. *Stroke*. 2019;50:1026–1031. doi: 10.1161/STROKEAHA.118.023927
50. Puntmann VO, Valbuena S, Hinojar R, Petersen SE, Greenwood JP, Kramer CM, Kwong RY, McCann GP, Berry C, Nagel E; SCMR Clinical Trial Writing Group. Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research, part I—analytical validation and clinical qualification. *J Cardiovasc Magn Reson*. 2018;20:67. doi: 10.1186/s12968-018-0484-5
51. Vaidya K, Arnott C, Martínez GJ, Ng B, McCormack S, Sullivan DR, Celermajer DS, Patel S. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study. *JACC Cardiovasc Imaging*. 2018;11(pt 2):305–316. doi: 10.1016/j.jccmg.2017.08.013
52. Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT, Hunn A, Bottomley A, Regnault A, Chan AW, et al; SPIRIT-PRO Group. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO Extension. *JAMA*. 2018;319:483–494. doi: 10.1001/jama.2017.21903
53. Marquis-Gravel G, Moliterno DJ, Francis DP, Juni P, Rosenberg YD, Claessen BE, Mentz RJ, Mehran R, Cutlip DE, Chauhan C, et al. Improving the design of future PCI trials for stable coronary artery disease: JACC state-of-the-art review. *J Am Coll Cardiol*. 2020;76:435–450. doi: 10.1016/j.jacc.2020.05.060
54. Iacobucci G. Inclisiran: UK to roll out new cholesterol lowering drug from next year. *BMJ*. 2020;368:m139. doi: 10.1136/bmj.m139
55. CSL's global role in battling COVID-19. 2020. March 3, 2021. <https://www.cslbehing.com/newsroom/2020/covid-19-cslb-facts>